Drug intelligence / Profile preview

shNEAT1a

Development stage
Preclinical
Lead developer
Kumamoto University
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

shNEAT1a is a short hairpin RNA (shRNA) construct designed to silence the expression of the long noncoding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1). In the context of hepatocellular carcinoma (HCC), NEAT1 has been identified as a key mediator of resistance to multi-kinase inhibitors such as sorafenib and lenvatinib. Mechanistically, shNEAT1a-mediated knockdown of NEAT1 disrupts the NEAT1-SOD2 axis, leading to the suppression of AKT signaling and the activation of the MAPK/ERK pathway. This molecular shift sensitizes liver cancer cells to targeted therapies, suggesting that NEAT1 inhibition could be a viable strategy to overcome drug resistance in liver cancer patients. While currently utilized primarily in preclinical research, it represents a targeted RNA-based approach to modulating oncogenic signaling pathways.

Other names
NEAT1-targeting shRNANEAT-1-targeting shRNANEAT 1-targeting shRNAshRNA targeting NEAT1shRNA-NEAT1shRNA-NEAT-1shRNA-NEAT 1
02

Targets

NEAT1 (Nuclear paraspeckle assembly transcript 1)

Beyond the preview

Go deeper on shNEAT1a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on shNEAT1a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call